Clearing Aβ or tau proteins that are alleged to induce AD has been the main strategy in the development of therapeutic agents; however, the results of clinical studies have been unsatisfactory, and there has been no definite treatment discovered for AD [2]. Here, MAPT is linked to Alzheimer disease.